Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

about

Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Item

http://www.wikidata.org/entity/Q39036192

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Degarelix for Treating Advance ...... E Single Technology Appraisal.

@en

Degarelix for Treating Advance ...... E Single Technology Appraisal.

@nl

type

Item

label

Degarelix for Treating Advance ...... E Single Technology Appraisal.

@en

Degarelix for Treating Advance ...... E Single Technology Appraisal.

@nl

prefLabel

Degarelix for Treating Advance ...... E Single Technology Appraisal.

@en

Degarelix for Treating Advance ...... E Single Technology Appraisal.

@nl

P1476

Degarelix for Treating Advance ...... E Single Technology Appraisal.

@en

P2093

Duncan Chambers

http://www.w3.org/2001/XMLSchema#string

Paul Tappenden

http://www.w3.org/2001/XMLSchema#string

Ruth Wong

http://www.w3.org/2001/XMLSchema#string

Sophie Whyte

http://www.w3.org/2001/XMLSchema#string

Timothy Gomersall

http://www.w3.org/2001/XMLSchema#string

P2860

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus

Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).

Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?

Prostate cancer screening and the management of clinically localized disease.

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

P2888

s40273-016-0481-1

P304

717-726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-016-0481-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shijie Ren

Lesley Uttley

P577

2016-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27943135

http://www.w3.org/2001/XMLSchema#string